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ABSTRACT
Tuberculous pericarditis (TBP) continues to wreak 
havoc across Sub-Saharan Africa (SSA). Despite more 
than 5 decades of treatment and research into TBP, 
we are not much closer to alleviating the suffering and 
mortality associated with this extrapulmonary mani-
festation of tuberculosis (TB). In the era of modern 
cardiology, diseases of the pericardium do not receive 
the same amount of research attention and investment 
as what diseases of lifestyle do. Interventional tech-
niques for their diagnosis and management do not 
extend much further than pericardiocentesis with 
appropriate laboratory investigations. They also do not 
provide the potential for the development and use of 
consumable equipment, or that of expensive drugs and, 
consequently, fi nancial investment into their research 
and development is not forthcoming. Diseases of the 
pericardium do, however, remain important within the 
discipline that we practice and TBP in particular 
deserves our continuous efforts and attention. It is 
unfortunate to acknowledge that we have not made 
much of an impact on this ancient foe over the last 50 
odd years. Despite the World Health Organisation 
(WHO) declaring TB a global emergency in 1993, more 
than 20 years later we are not much better off. In 2013 
an estimated 9 million people developed the disease 
and 1.5 million died from it.(1) TBP is predominantly a 
disease of SSA and it requires a solution from the very 
region which it torments.  SAHeart 2016;13:104-111
INTRODUCTION
Mycobacterium tuberculosis (MTB) has been ravaging mankind 
through the ages with the earliest evidence of infection dating 
back to the Neolithic era, 9 000 years ago, confirmed by the 
extraction of MTB DNA from archeological human remains.(2) 
It is considered to be the most lethal pathogenic killer in human 
history, with the developing world experiencing 90% of 
cases.(1) South Africa (SA) continues to have the highest 
incidence and prevalence of TB in the world and this places 
an immense burden on the health of our population.(1) The 
developed world has enjoyed a low incidence of the disease, 
with new cases predominantly identified in foreign-borne 
residents and immigrants from developing nations. However, an 
inevitable resurgence in infection rates threatens Europe, given 
the recent explosion in the number of refugees fleeing to that 
continent. In SSA the high rate of co-infection with the Human 
Immunodeficiency Virus (HIV) is associated with increased 
mortality. In 2013 the prevalence of HIV in TB incident cases in 
SA was 61%, second only to Zimbabwe at 72%.(1) Despite the 
global health threat posed by this age-old disease, which is 
responsible for more deaths worldwide than any other cause, 
there has been little in the way of new drug development. The 
standard short-course therapeutic regime has been in use for 
over 30 years.(3) The emergence of multidrug resistant (MDR), 
extensive drug resistant (XDR) and total drug resistant (TDR) 
strains poses a significant threat, particularly in SA where the 
rate of MDR infection stands at 1.8% of all new cases and 
6.7% of retreatment cases.(4) SA also has the highest number of 
XDR cases in the world with 10% of the MDR group being 
XDR.(4) Extra-pulmonary infections account for 10 - 42% of 
TB cases with TBP occurring in 1 - 2% of patients with pul-
monary TB.(5,6) In SA, TB accounts for 50 - 70% of large 
pericardial effusions in HIV negative patients and >90% in 
those who are HIV positive.(7) The morbidity and mortality 
remain high despite anti-TB chemotherapy with a case fatality 
rate of 26% at 6 months, rising to 40% in patients with HIV 
co-infection.(8) Rifampicin based anti-tuberculous therapeutic 
regimens decreased the risk of constrictive pericarditis (CP), 
the leading cause of mortality, from 50% to 14 - 40%.(9) This 
remains an unacceptably high case rate. To date, no adjunctive 
therapy has been proven to alter the rate of death from 
constriction in TBP.(10-13) Tuberculous meningitis, another 
extrapulmonary manifestation of the disease, which is also 
responsible for considerable morbidity and mortality, has 
recently been the target of an attempt at an intensified 
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therapeutic regimen. In adults with the disease in Vietnam, an 
increased dose of rifampicin, and the addition of levofloxacin 
to the standard regimen, disappointingly did not reduce the 
overall mortality that stands at 28%.(14) In TBP, extending the 
short-course treatment regimen from 6 - 9 months, does not 
alter outcomes.(15)
Regardless of the global health threat posed by TB, inadequate 
funding into TB research and development (R&D) in 2014 left 
a funding gap of $1.3 billion measured against the $2 billion 
annual investment required for by the Global Plan to Stop TB 
2011 - 2015.(16) Despite the shortfall in TB R&D funding over 
the past 5 years, strides have been made into the development 
of new drugs against drug-resistant TB, a more rapid diagnostic 
test (validated for use in pulmonary TB) and to re-invigorate 
the once-dormant field of TB vaccine research. Bedaquiline, 
the first drug in over 40 years to have a new mechanism of 
action against TB, inhibits mycobacterial ATP synthase.(17) In 
2012 it received accelerated FDA approval for use in MDR 
pulmonary TB. Although there have been recent advances in 
TBP, controversies and challenges still exist and this article will 
outline specific areas where attention should be focused.
ESTABLISHING THE DIAGNOSIS
In areas with a high prevalence of TBP, empiric therapy is 
recommended when other potential causes have been 
excluded. Excluding other potential aetiologies of pericarditis is 
not always a simple undertaking, and erroneously exposing 
patients without a diagnosis of TBP to antituberculous chemo- 
therapy is not without risk. In regions where clinicians do not 
have the ability to undertake pericardiocentesis, or where 
pericardial fluid collections are too small for safe needle 
aspiration, a clinical scoring system can be used to establish a 
probable diagnosis with a sensitivity and specificity of 86% and 
85% respectively (Table 1).(18) Establishing a confirmed diagnosis 
remains challenging as TB culture of pericardial fluid is slow and 
insensitive and direct examination for acid fast bacilli (AFBs) has 
a low yield.(19) Clinicians therefore rely on diagnostic algorithms, 
incorporating biochemical markers such as adenosine deami-
nase (ADA) and unstimulated interferon gamma (uIFN-γ), to 
make a presumptive diagnosis of TBP.(20) Whilst an ADA level 
≥40IU/L in the setting of an exudative effusion with a lym-
phocyte: neutrophil ratio >1 has a high sensitivity and specificity 
for the disease, it does not come without its challenges.(18,20) 
An accurate determination of ADA is frequently not possible, 
particularly in the setting of blood stained effusions. A pericardial 
fluid uIFN-γ level >50 pg/ml is both more sensitive, and specific, 
than ADA for the diagnosis of TBP.(18,20) It is, however, not 
widely available as a diagnostic test in SSA due to its high cost 
and the fact that it requires expertise on the part of the 
laboratory performing the test to deliver a reliable result. To 
date its application has been predominantly in a research 
setting. Xpert-MTB/RIF, an automated nucleic acid amplification 
test, which can rapidly detect both MTB DNA (within 2 hours) 
and assess for possible Rifampicin resistance, has been approved 
for sputum evaluation in the setting of possible pulmonary TB. 
It has been demonstrated to have a low sensitivity in the setting 
of pleural TB, 46% vs. 99% by culture, and more recently its 
potential value was evaluated in the setting of pericardial 
disease on pericardial fluid specimens.(21,22) It achieved a low 
sensitivity of 63,8% and was found to be inferior to both ADA 
and uIFN-γ in microbiologically confirmed TBP.(22) Its potential 
value in the evaluation of pericardial tissue specimens remains 
unknown. An older PCR assay was evaluated in 20 patients, 
who underwent open surgical pericardial biopsy, on both fluid 
and tissue samples.(23) The sensitivity of PCR was higher for 
tissue specimens (80%) than fluid specimens (15%) and we are 
therefore evaluating the potential diagnostic accuracy of the 
newer Xpert-MTB/RIF assay on both pericardial fluid and tissue 
specimens obtained via a non-surgical percutaneous approach.
Until recently, access to pericardial tissue required invasive sur-
gical techniques known to both prolong hospital stay and 
increase patient morbidity and mortality. Percutaneous peri-
cardioscopy is a minimally invasive technique with a low 
complication rate for obtaining pericardial tissue, allowing for a 
more detailed evaluation of the diseased pericardium than 
evaluation of fluid specimens alone.(24) Through the introduction 
of a flexible fibre-optic scope into the pericardial space, both 
the epicardium and parietal pericardium can be assessed for 
areas of inflammation, allowing targeted biopsies to be acquired 
under direct vision (Figure 1). It has been demonstrated to have 
a low risk profile in large series, with not a single reported 
mortality attributable to the procedure.(24-28) The risk of the 
procedure is the inherent risk associated with the pericardio-
centesis procedure itself, and not pericardioscopy. In the 
Marburg registry, including 259 patients, pericardial biopsy by 
this technique allowed for a more definitive aetiological clas-
sification and targeted therapy in patients presenting with 
pericardial effusion in a first world setting.(26) The investigators 
in this registry successfully used a 6-French endomyocardial 
bioptome to acquire suitably representative tissue samples 
without an increase in procedural related adverse events. It has 
TABLE 1: The Tygerberg Diagnostic Index Score for TBP. 
A score ≥6 has a sensitivity of 86% and a specificity of 85% for the 
diagnosis of TBP.
Criterion
Weight loss (>10%)
Night sweats
Fever >37.2° Celsius
Serum globulin >40g/l
White cell count <10 x 109/l
Score 
1
1
2
3
3
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also been proven that extensive sampling (18 - 20 biopsies) 
improves the diagnostic yield of the procedure, whilst not 
impacting on procedural safety as compared to limited sampling 
of 4 - 6 biopsies.(24) The probability of diagnosing an infiltrate is 
also significantly higher in epicardial than in parietal pericardial 
sampling (80% vs. 7% in neoplastic disease, and 93% vs. 14% 
in inflammatory disease).(29) Preferential epicardial sampling, 
directly from the surface of the beating heart, does not 
adversely influence procedural safety.(29)
In our pilot study, which included 31 patients, we confirmed 
that it is a minimally invasive procedure with low procedural 
risk when applied to a population with a high prevalence of 
TBP.(30) By means of limited sampling of 6 biopsies, using a 1mm 
bioptome, representative samples could safely be acquired in 
27 participants. A diagnosis of definite TBP was established in 
55%, all of which were diagnosed on tissue specimens, whilst 
fluid evaluation missed the diagnosis in 20%. A rapid diagnosis 
could be achieved in 73% by the demonstration of AFBs on 
tissue samples, allowing clinicians to confidently institute anti-
TB chemotherapy (Figure 2). All fluid samples were AFB 
negative, and a fluid based diagnosis was reliant on TB culture, 
with a mean time to positive culture of over three weeks. An 
alternative diagnosis was established in 17%, who could be 
spared unnecessary TB chemotherapy. A single case of MDR-
TB was identified in this cohort, again diagnosed on a tissue 
specimen and missed on TB culture of pericardial fluid.(30) 
Establishing a definite diagnosis of TBP, and allowing for drug-
sensitivity testing, is of paramount importance now that we 
have entered the era of MDR, XDR and TDR strains of the 
disease. It is estimated that only 10% of MDR TB cases are 
diagnosed worldwide, and only half of them receive appropriate 
treatment.(31)
Percutaneous pericardioscopy remains a research tool, and it is 
unlikely that its use will disseminate farther afield than spe-
cialised pericardial disease research centers due to the 
infrastructure required to perform the technique. It does, 
however, offer the opportunity to safely acquire pericardial 
tissue specimens and has been demonstrated to potentially 
offer superior diagnostic accuracy over the evaluation of fluid 
samples alone in a population with a high prevalence of TBP. 
This can be done with a limited sampling technique and 
comparatively smaller sampling forceps compared to studies 
performed in the developed world.(30) No reliable data is 
available on mycobacterial speciation, strain typing, and the 
incidence of drug resistant disease or mycobacterial tropism in 
the setting of TBP in a population with, and without, HIV co-
infection. A recent study, undertaken at our institution, assessing 
the effect of mycobacterial genotype and its association on 
disease phenotype in a paediatric population, included only one 
single patient with pericardial disease out of a cohort of 392 
subjects.(32) Pericardial involvement is far less common in the 
paediatric population and thus assessment in the adult setting is 
required. Apart from an impaired host immune response 
favouring the development of extrapulmonary disease, the 
authors hypothesised that different MTB strains, in particular 
the Beijing genotype, could cause distinct clinical disease 
phenotypes, as suggested by animal studies in which different 
MTB strains evoke markedly different immunopathological 
host responses. Extrapulmonary strains have previously been 
demonstrated to infect macrophages more efficiently whilst 
also being more infectious than pulmonary strains, a feature 
suggesting greater pathogenicity.(33) The Beijing genotype, which 
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FIGURE 2: A single red, rod-shaped TB bacillus fi xed by acid-
fast stain on a pericardial tissue specimen obtained by percuta-
neously directed pericardial biopsy.
FIGURE 1 and accompanying online video: Intrapericardial 
view during percutaneous pericardioscopy with targeted epi-
cardial biopsy. Biopsy forceps visible at 11 o’clock.
107
20
16
Vo
lu
m
e 
13
 N
um
be
r 2
predominates in South Africa, is well known to increase the 
risk of central nervous system involvement and more severe 
pulmonary disease. Whether or not this is the case for 
pericardial disease remains to be defined in a study by our 
research group. In the report on paediatric disease, the Beijing 
genotype was associated more commonly with extra-thoracic 
disease than the LAM genotype, suggesting that LAM strains 
have less ability to disseminate.(32) No evidence of mixed MTB 
genotype infection was demonstrated in any of the participants 
of this paediatric cohort.
Whilst rates of drug resistance in pulmonary disease are well 
characterised, the incidence in pericardial involvement is cur-
rently unknown. A study conducted in KwaZulu-Natal has 
revealed that S/Quebec strains (34%) were more commonly 
associated with MDR disease and LAM strains (89%) with 
XDR-TB, whilst Beijing strains were predominantly responsible 
for drug susceptible disease.(34) Although they evaluated 297 
isolates from 227 patients with TB, with almost 25% having 
extra-pulmonary disease, the authors did not identify the 
various sites of extrapulmonary involvement and the incidence 
for pericardial disease remains unknown. 
An accurate point of care test for establishing the diagnosis of 
TBP does not exist. We are currently exploring the potential 
of developing such a test by identifying a biosignature of a 
combination of cytokines. Pericardioscopy offers the oppor-
tunity to accurately validate such a combination of cytokines 
against a confirmed histological and microbiological diagnosis 
of MTB pericarditis, as provided by pericardial tissue speci-
mens. It is possible that a higher yield of MTB can be gained 
with the acquisition of larger tissue fragments. A pilot trial is 
planned to evaluate the safety of employing a larger peri-
cardioscope that will accommodate a 6-French bioptome in 
our patient population.
THE CONTROVERSIAL ROLE OF STEROIDS
Attempts at modulating the host inflammatory response to TBP 
with glucocorticoids, in an attempt to prevent constriction, 
reach as far back as 1959 when 14 patients received both TB 
therapy and adjunctive high-dose steroids, whilst another 14 
received TB therapy alone. There was no difference in the 
development of CP in either of the two groups.(10) A systematic 
review of randomised controlled trials, evaluating the potential 
advantage of adjunctive corticosteroids, found no significant 
beneficial effect of steroids on either the re-accumulation of 
pericardial effusion or the progression to CP.(35)
In our local experience complete percutaneous drainage of a 
tuberculous effusion, in combination with anti-tuberculous 
therapy, is associated with an extremely low risk for constriction 
and cardiac death.(9,11) One small trial has shown that the addi-
tion of intrapericardial urokinase may facilitate this approach.(12) 
Furthermore, in an underpowered trial of 57 patients, the 
administration of intrapericardial steroids did not influence the 
risk of developing constriction.(11) Patients with effusive constric-
tive pericarditis (ECP) were excluded from enrolment and 
those with purely effusive disease were randomised to 1 of 3 
arms. These included antituberculous chemotherapy for 6 
months with placebo, oral prednisolone or intrapericardial 
triamcinolone. All participants underwent complete pericardial 
drainage with intermittent daily aspiration until <100mls/24hr 
had been drained. At one year’s follow up there was only 1 
case of CP, having occurred in a patient randomised to oral 
prednisone. The authors concluded that short course anti-
tuberculous chemotherapy, in combination with extended peri-
cardial drainage, results in excellent outcomes in patients with 
effusive TBP. More recently, the IMPI trial evaluated the value 
of adding adjunctive high-dose oral prednisolone for 6 weeks 
to anti-TB therapy in both HIV+ and - patients with TBP.(13) 
Two thirds of the 1 400 participants underwent pericardio-
centesis and a definite diagnosis of TBP was established in 
approximately 16%. Adjunctive oral prednisolone had a neutral 
effect on the combined primary outcome of death from all 
causes, cardiac tamponade requiring pericardiocentesis and 
pericardial constriction. In the HIV positive group it was 
associated with an adverse outcome in that it led to an 
increase in HIV-related malignancies and a trend towards HIV-
related death. The rate of constriction, a secondary outcome, 
was reduced by 46% regardless of HIV status without trans-
lating into a reduction in mortality. This is a difficult finding to 
explain given that it is the very development of constriction that 
is responsible for the late mortality seen in TBP. The 2015 
European Society of Cardiology (ESC) guidelines for the 
diagnosis and management of pericardial diseases has therefore 
allocated a class IIb, level of evidence C recommendation to 
the addition of adjunctive corticosteroids in HIV negative 
patients with TBP.(36) They should clearly be avoided in patients 
who are HIV positive. The recommendations on adjunctive oral 
steroid therapy still need to be updated in the guidelines issued 
by the American Thoracic Society, Centers for Disease Control 
and Infectious Diseases Society of America, in which they are 
recommended in all cases of TBP, regardless of HIV status.(37) 
The IMPI trial protocol relied heavily on clinical findings sup-
portive of constriction, and did not incorporate the use of 
mitral annular Tissue Doppler Imaging (TDI) in the transthoracic 
echocardiographic (TTE) criteria for establishing the diagnosis 
of constriction.(38) Radial and circumferential ventricular expan-
sion are limited in constriction as the myocardium is tethered to 
the pericardium, however, the subendocardial longitudinal 
fibers are free to lengthen and thus early annular diastolic tissue 
velocity (eΙ) is correspondingly normal or supra-normal.(39) This 
is a paradoxical finding in the setting of elevated left atrial filling 
pressures and the E/eΙ ratio is therefore low, despite an ele-
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vated left ventricular end-diastolic pressure, producing the TTE 
feature of annular paradox.(40) Understandably, given that the 
IMPI trial was conducted across the continent where resources 
and expertise are limited, invasive haemodynamics were not 
employed to confirm a suspected diagnosis of CP. This is in 
line with standard practice, provided an accurate diagnosis of 
constriction can be confirmed by detailed TTE evaluation incor-
porating mitral annular TDI.(36) More recently, respiratophasic 
septal shift, in combination with either a hepatic venous expir-
atory diastolic flow reversal ratio ≥0.79, or a medial annular TDI 
eΙ ≥9cm/sec has been demonstrated to be 87% sensitive and 
91% specific for CP.(41) It is therefore possible that subclinical 
cases of constriction went undiagnosed in this patient cohort. 
This offers a potential explanation for why a perceived reduc-
tion in constriction failed to translate into a derived mortality 
benefit in the group receiving adjunctive corticosteroid therapy. 
In the modern era, a detailed TTE, including: annular TDI and 
hepatic venous Pulsed-wave (PW) Doppler (Figure 3) should 
be undertaken in all patients with suspected CP.(41) Annular 
TDI assessment has the added advantage of identifying 
restrictive cardiomyopathy as a cause for elevated left atrial 
filling pressures. Here the medial mitral annular early diastolic eΙ 
velocity will be <8cm/sec due to underlying primary myocardial 
disease.(40,42)
It is unlikely that all HIV negative patients with TBP stand to 
derive benefit from the addition of high-dose adjunctive corti-
costeroids as the majority will not go on to constrict, provided 
they undergo complete pericardial drainage and remain com-
pliant on their antituberculous therapy. It would therefore be 
prudent to identify the group which is at highest risk of going on 
to develop CP as they stand to derive maximum benefit from 
adjunctive steroid therapy. Such a group remains undefined and 
clarity is required in this regard. It is our opinion that it is the 
group presenting with effusive-constrictive physiology that 
stands to benefit most and we are currently exploring this 
option. Effusive-constrictive pericarditis (ECP), which is due 
to visceral pericardial restriction, is traditionally a diagnosis 
established by invasive haemodynamics, requiring that right 
atrial (RA) pressure remains above 10mmHg or does not fall 
by 50% following complete pericardial fluid drainage with the 
normalisation of intrapericardial pressure.(43) Other potential 
causes for a persistently elevated right atrial pressure, after 
the normalisation of intrapericardial pressure post pericardio-
centesis do however exist, and recent data from our group 
demonstrates this fact. The finding of an elevated RA pressure 
does therefore not necessarily equate to constrictive physiology 
without proving the two hallmark physiological features of CP, 
namely the dissociation of intrathoracic and intracardiac pres-
sures and enhanced interventricular dependence. Our group 
has recently demonstrated that ECP can be accurately defined 
by detailed TTE evaluation, including TDI, before and after 
pericardiocentesis (under review for publication). Furthermore, 
this study revealed that in half of those who would be classified 
as having ECP by traditional criteria, the hallmark (and most 
sensitive and specific) physiological sign of CP on invasive 
haemodynamics, i.e. systolic discordance of left ventricular and 
right ventricular pressures, was absent. In this cohort TTE 
criteria for establishing a diagnosis of ECP correlated very well 
with the invasive demonstration of the dissociation of intra-
thoracic and intracardiac pressures, and also that of enhanced 
interventricular dependence, and not with elevated RA pressure 
after the normalisation of intrapericardial pressure. This would 
suggest that the traditional criteria for diagnosing ECP are over 
sensitive and outdated. With the availability of this new data an 
assessment of this particular syndrome of TBP can now be 
undertaken without the need for invasive, and potentially more 
hazardous, right heart catheterisation for research purposes. It 
is our hypothesis that it is this group who will potentially derive 
maximum benefit from the addition of high-dose adjunctive 
oral corticosteroid therapy in preventing the development of 
constriction, and ultimately the mortality associated with this 
pericardial syndrome.
CONSTRICTION: SURGICAL TIMING, 
APPROACH, AND THE RISK OF RECURRENCE
CP is a potentially curable cause of diastolic heart failure, 
generally developing within 6-months of presentation in the 
effusive stage.(44) The incidence of tuberculous CP is 31,65 cases 
FIGURE 3: Hepatic venous PW-Doppler assessment in a 
patient with CP. The hepatic venous expiratory early diastolic 
reversal ratio is defi ned as the expiratory diastolic reversal 
velocity divided by the diastolic forward velocity. In this example 
the ratio is 1.24.  It is a refl ection of the two hallmark physiological 
features of CP: the dissociation of intrathoracic and intracardiac 
pressures and enhanced interventricular dependence. Relatively 
faster left-sided cardiac chamber fi lling during expiration causes 
respiratophasic ventricular septal shift into the right ventricle. 
This reduces the hepatic vein forward velocity and exaggerates 
the late diastolic reversal velocity. 
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per 1 000 person years, second only to purulent disease at 
52,74 cases per 1 000 person years.(45) The 2015 ESC guide-
lines for the diagnosis and management of pericardial diseases 
provides a Class IC recommendation only for anti-TB therapy 
as a means to prevent constriction, whilst both adjunctive 
steroids (in HIV negative patients), and intrapericardial uro-
kinase each receive a Class IIb, C recommendation.(36) Approxi-
mately 60% of patients with early tuberculous constriction will 
respond to antituberculous therapy.(46) Pericardiectomy is 
recommended if after 4 - 8 weeks of therapy the patient’s 
condition remains unchanged, or deteriorates.(36) This remains 
controversial due to limited data, however the general con-
sensus is that resection is associated with lower surgical 
morbidity and mortality earlier in the course of pericardial 
adhesion, and before the onset of myocardial atrophy. No 
recommendation is provided for the preferred surgical access 
site or completeness of pericardial resection in TBP-CP 
within the guideline document. The choice of surgical approach, 
i.e. median sternotomy vs. left anterolateral thoracotomy is 
currently not definitive and is thus determined by the surgeon’s 
preference.(47) Anecdotal reports have indicated good operative 
results associated with the surgical technique used.(47,48,50) In a 
series from 1982, including 109 patients, 31 with histologically 
proven TB and the rest with probable TB, all underwent peri-
cardiectomy via a left anterolateral thoracotomy.(48) Via this 
approach the pericardium could be mobilised anteriorly 
between both phrenic nerves, extended to the right ventricular 
outflow tract and also posteriorly and inferiorly over the dia-
phragmatic surface of the heart (radical pericardiectomy). The 
in hospital mortality rate in this series was just 3% and only 1 
case required a revision pericardiectomy at one year for recur-
rent constriction. The author reported a suspected low rate of 
recurrence. This was however judged solely on the basis of the 
clinical signs of a suspected recurrence of CP and TTE imaging 
was not employed. Furthermore, many patients did not attend 
follow up appointments and the low rate of recurrence was 
attributed to the absence of requests for disability or death 
certification. The study was also conducted before the era of 
HIV infection and the results are not necessarily applicable to 
our current practice. Interestingly, the potential advantage of 
this approach over that of a median sternotomy in offering 
access to wide pericardial resection, was more recently evalu-
ated with 16 en bloc cadaver specimens and the review of 
surgical notes of both techniques.(49) The investigators included 
a review of the surgical records from the series published in 
1982 as part of the analysis. Although the anterior pericardium 
between phrenic nerves was found to constitute 58% of total 
selected pericardial area, only 26% of the total pericardium 
over the left ventricle was accessible from that approach. A left 
anterolateral approach was found to offer wider access to the 
left ventricle and 37% of total pericardial area could be acces-
sed. This information therefore offers a functional anatomical 
perspective for the choice of left anterolateral thoracotomy as 
a surgical approach for pericardiectomy. In a retrospective 
report conducted during the HIV era, including 121 patients 
who underwent median sternotomy for CP, the 30-day peri-
operative mortality rate was excessively high at 14%.(50) In other 
series reported worldwide this rate stands at 6 -10%(51). Only 
11.6% were HIV positive with 29.8% of cases having confirmed 
TBP with a further 61.2% having presumed TBP as the cause of 
their constriction. A preoperative low serum-Na+ and/or New 
York Heart Association (NYHA) class IV effort tolerance were 
found to be independent predictors of early mortality. There 
were no early deaths in the HIV positive group, albeit this did 
make up a small percentage of the patient group. Sixty six 
percent of participants had a preoperative NYHA class III or 
IV effort tolerance, and it is in these groups where most of the 
30 day mortality occurred, making up 11% of the total 14% of 
those who succumbed. This is a likely indicator of end-stage 
disease complicated by myocardial atrophy. It is indeed well 
established that the group with a low cardiac index of 
≤1.2L/m2/min at rest derive little or no benefit from surgery as 
surgical risk outweighs the potential benefit of symptomatic 
improvement.(52) The investigators did not report on the rate 
of recurrent pericardial constriction, which to date remains 
undefined in the group with HIV co-infection undergoing 
pericardiectomy via median sternotomy. In a smaller cohort of 
47 patients (46.8% due to TBP) from Turkey, followed out to 
61.2 ± 66 months, the rate of recurrent CP was zero.(53) All but 
one patient underwent pericardiectomy via median sternotomy 
with radical pericardial resection. HIV status was not reported 
on and most patients had a preoperative NYHA class of II or III. 
The 30 day mortality rate was correspondingly low at 8.5%. 
In the developed world, where previous surgical pericardio-
tomy and prior chest radiotherapy are the most common 
aetiologies of CP, repeat pericardiectomy is associated with a 
perioperative mortality rate of 20% at 30 days.(54) The most 
common cause for this recurrence of constriction was found to 
be incomplete pericardial resection with residual posterolateral 
or diaphragmatic pericardium.(54) The local report from 1982, 
and the follow up anatomically based study, would therefore 
suggest that a left anterolateral approach would be the most 
suitable approach for undertaking a radical pericardiectomy in 
a population with a high prevalence of TBP. In our local 
experience a limited anterior pericardial resection, phrenic 
nerve to phrenic nerve, is most commonly employed via 
median sternotomy for procedural safety reasons. The decision 
to extend this to include the posterolateral and diaphragmatic 
pericardial surfaces is assessed on a case-by-case basis, weighing 
up the risk of intraoperative haemorrhage against that of 
the potential for recurrence of CP. Whether or not peri-
cardiectomy via median sternotomy is associated with recur-
rence of CP in our population is currently not known. 
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CONCLUSION
TBP continues to cause unacceptably high rates of morbidity 
and mortality despite more than 6 decades of antituberculous 
medical therapy directed against it. Regardless of modern 
advances in medicine, this is clearly not a disease for which 
there will be a suitable solution in the near future. It remains a 
diagnostic challenge and the development of a point of care 
test, stringently evaluated against confirmed TBP by demon-
stration of the bacillus in fluid or tissue specimens, would be of 
immense value to the diagnosis and management of the disease 
in SSA. The potential value of intrapericardial antituberculous 
chemotherapy should be explored as a possible means of 
impacting the time to cure and reducing the associated 
morbidity and mortality. In 2012 the worldwide incidence of 
MDR TB stood at 450 000 whilst the rates of drug resistant 
TBP still remain undefined. Bedaqualine, delaminid and pre-
tomanid, drugs in development for resistant TB, are highly 
protein-bound which may influence their availability within the 
pericardial space and their potential value in the treatment of 
resistant pericardial disease will have to be assessed. In HIV 
negative patients who present with tuberculous ECP, the 
potential value of adjunctive steroids should be evaluated 
against those who present with pure effusive disease and 
undergo complete pericardial drainage. It is highly probable that 
those in the effusive-constrictive phase stand to benefit most 
from immunomodulation of the host response. A detailed TTE 
by an experienced echocardiographer, employing TDI and 
hepatic venous PW-Doppler, can confidently diagnose con-
strictive pericarditis and differentiate it from restrictive 
cardiomyopathy. The application of the recently proposed 
Mayo Clinic TTE criteria for the diagnosis of CP should be used 
to establish, or refute, a possible diagnosis of tuberculous CP. 
The applicability of these criteria should also be evaluated in 
establishing a diagnosis of recurrent CP in a population with a 
high prevalence of TBP. In those with constriction, a left antero-
lateral thoracotomy would appear to offer a more suitable 
approach for achieving successful radical pericardiectomy vs. 
that via median sternotomy. Most surgical centers in SA 
undertake pericardiectomy via a median sternotomy and the 
rate of recurrent constriction in this group needs to be formally 
evaluated against that of an approach via left anterolateral 
thoracotomy in the HIV era. TBP remains a challenging disease, 
to both diagnose and manage, and it should be an area of 
research priority within our academic cardiology and cardio-
thoracic surgery units in SSA. It is predominantly a disease of 
the African continent that requires a solution from within this 
region.
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